

Vidac Pharma announces international experts' participation to "Toposteric" Round Table at HTID5 in Paris Oct 24-25

Vidac Pharma is happy to announce it succeeded in bringing to the HTID5 Roundtable the participation of world specialists.

REHOVOT, ISRAEL, August 30, 2023 /EINPresswire.com/ -- Under the Organization of Dr Alain Herrera previously head of the Oncology Franchise at Sanofi around the new paradigm for drug discovery proposed by [Vidac Pharma](#), the Company is



happy to announce it succeeded in bringing to this Roundtable the participation of world specialists. Prof Wolfgang Link from the Spain CSIC and Cofounder of Refoxy Pharmaceuticals, Berlin, is a world specialist on Protein mislocation and will show the pivotal role of mis localization of subcellular proteins in pathogenesis of numerous human diseases. Dr Lyora

Aharonov from EMRIS and Dr Sharon Merims from Hadassah Hospital & Medical School in Israel will describe prevention of Skin Toxicities induced by EGFR inhibitors used in Cancer treatment by locally blocking the drug-receptor interaction. Dr Laetitia Linares, Director of Research at the French INSERM, will show the passage from discovery of Chromatinian MDM2 to the development of breakthrough anticancer Therapy.

The Moderator of this Round table, Prof Max Herzberg, Chairman of Vidac Pharma Holding (UK and Israel) and

“

It is expected that many Pharma and Pharma specialized funds will attend the gathering, a two roundtables session around new approach to Cancer.”

Dr. Max Herzberg

inventor of the "Toposteric" word and paradigm will show the Clinical efficacy of the Company Drug products and candidates in both Carcinoma and Lymphoma Cancer and the potential of new molecules for treatment of solid tumors in the Company pipeline. It is expected that many Pharma and Pharma specialized funds might attend the gathering, a two roundtables session around new approach to Cancer.

Rehovot (Israel), London (UK) and Paris (FR)

About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.

Disclaimer

The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC

Dr. Max Herzberg

20-22 Wenlock Road

London N1 7GU

United Kingdom

<http://www.vidacpharma.com/>

investors@vidacpharma.com

+972-54-4257381

+972 (0)779300647

Max Herzberg

Vidac pharma Holding Plc

72544257381

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/652547991>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.